Drugs / Hydrocortancyl
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03380559 | Apr 2019 → Jul 2021 | epicondylitis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT00804531 | Apr 2009 → May 2015 | — | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01694134 Comparator | Jul 2012 → Mar 2017 | infectious discitis, lumbar disk disease | University Hospital, Montpellier | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrocortancyl | “Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)” NCT03380559 ↗ |
| Modality | Other / unclassified | “A single glucocorticoid intradiscal injection (GC IDI)” PMID 28319997 ↗ Mar 2017 |
| Route | Other | “Hydrocortancyl 25 mg/ml - 1 ml intra-discal route” NCT00804531 ↗ |